Thursday, April 22, 2021 11:31:18 AM
Dilution at this point, is for the most part, not relevant. The BRTX shares in question, have been available for five months and the stock is still OK, moving up overall, actually the current price, even though it is down, is double what it was since the time it was selling for $0.006 or less last December. I believe that BRTX will continue to price appreciate once it is a reporting company and will do so until such time as investors/traders decide it's time to take their money off the table. That's how the market works. One only needs to read the numbers for the available stock, the float, and more to see that there is no real dilution selling happening...nearly the same numbers every day. What does that tell you about dilution? It just doesn't hold water.
The smart strategy is having these shares available to use for many reasons in the future such as attracting investors, employee compensation, etc. These shares offer the company a unique advantage. Normally a company has to get permission from the stockholders to issue more stock to the public for capital investment. That roadblock has been removed. BRTX never will have to ask for permission for a capital raise from us shareholders. That means FREEDOM.... they already have plenty of stock to use to grow the company. They own a majority of the stock already and, I'm sure, will not be selling soon. Lance is buying 15 billion shares himself.
The dilution is not a disadvantage, it is a huge ADVANTAGE if used properly. I have complete confidence that Lance knows how to do that.
HODL
Recent BRTX News
- BioRestorative Therapies Receives Patent Allowance for ThermoStem® Metabolic Disease Program • GlobeNewswire Inc. • 10/31/2024 11:00:00 AM
- BioRestorative Therapies to Participate in Upcoming UBS and Maxim Group Investor Events • GlobeNewswire Inc. • 10/10/2024 11:00:00 AM
- BioRestorative Therapies to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference • GlobeNewswire Inc. • 10/03/2024 08:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/23/2024 08:33:16 PM
- BioRestorative Therapies’ IFATS 2024 Presentation to Feature ThermoStem® Platform’s Potential to Deliver a Superior Efficacy and Tolerability Profile Over GLP-1 Drugs • GlobeNewswire Inc. • 09/19/2024 10:55:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:30:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/13/2024 08:11:03 PM
- BioRestorative Therapies Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/13/2024 08:05:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/08/2024 08:23:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 08:47:26 PM
- BioRestorative Therapies to Report Second Quarter 2024 Financial Results and Host Conference Call on August 13, 2024 • GlobeNewswire Inc. • 08/06/2024 08:05:00 PM
- BioRestorative Therapies’ Chief Scientist Named New Section Editor of the Prestigious Journal of Translational Medicine • GlobeNewswire Inc. • 07/23/2024 11:10:00 AM
- BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program • GlobeNewswire Inc. • 06/27/2024 11:40:00 AM
- BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 06/17/2024 11:05:00 AM
- Shares of Biotech MicroCap Rip on Licensing Talks • AllPennyStocks.com • 06/13/2024 03:40:00 PM
- BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem® Metabolic Disease Program • GlobeNewswire Inc. • 06/13/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 06/11/2024 08:28:30 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 06/11/2024 08:23:50 PM
- BioRestorative Therapies, Inc. to attend the Jefferies 2024 Healthcare Conference • GlobeNewswire Inc. • 06/04/2024 12:50:00 PM
- BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice • GlobeNewswire Inc. • 05/24/2024 11:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 08:51:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 08:45:27 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/16/2024 09:17:17 PM
- BioRestorative Therapies Provides First Quarter 2024 Business Update • GlobeNewswire Inc. • 05/14/2024 08:10:00 PM
- BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity • GlobeNewswire Inc. • 05/08/2024 11:30:00 AM
FEATURED North Bay Resources Announces Assays up to 9.5% Copper at Murex Copper Project, British Columbia • Nov 4, 2024 9:00 AM
Rainmaker Worldwide Inc. Announces Strategic Partnership Between Miranda Water Technologies and Fleming College • RAKR • Nov 4, 2024 12:03 PM
Rainmaker Worldwide Inc. to Assume Direct, Non-Dealer Sales of Miranda Water Technologies in U.S. and Mexico in First Quarter of 2025 • RAKR • Nov 4, 2024 8:31 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM